Saniona AB (publ) (STO:SANION)
Sweden flag Sweden · Delayed Price · Currency is SEK
9.14
-0.43 (-4.49%)
Aug 1, 2025, 5:29 PM CET

Saniona AB Company Description

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom.

It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; and ACP-711, a positive allosteric modulator of GABAA α3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, a neurological disorder.

It also develops SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA α2- α3- and α5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; and SAN2465, a negative allosteric modulator to treat major depressive disorder.

In addition, the company’s other programs to treat epilepsy, Alzheimer’s, schizophrenia, and migraine.

It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer’s disease.

Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

Saniona AB (publ)
Saniona AB logo
CountrySweden
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees22
CEOThomas Feldthus

Contact Details

Address:
Murervangen 42
Glostrup, 2600
Denmark
Phone45 70 70 52 25
Websitesaniona.com

Stock Details

Ticker SymbolSANION
ExchangeNasdaq Stockholm
Fiscal YearJanuary - December
Reporting CurrencySEK
ISIN NumberSE0005794617
SIC Code2834

Key Executives

NamePosition
Jorgen Drejer Ph.D.Founder, Deputy Chief Executive Officer and Deputy Chairman of the Board
Thomas Feldthus M.Sc., MBACo-Founder and Chief Executive Officer
Dr. Pierandrea Muglia M.D.Chief Medical Officer
Johnny Stilou M.S.Chief Financial Officer
Janus Schreiber LarsenChief Operational Officer
Karin Sandager Nielsen Ph.D.Chief Scientific Officer